Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetes Mellitus, Type 1: full-pipeline trial registry
39 of 119 indexed Diabetes Mellitus, Type 1 trials are currently recruiting.
Corpus placement: #105 of 28,707 conditions by registered trial count.
119 US clinical trials · 39 currently recruiting · #105 of 28,707 conditions by registered trial count
Diabetes Mellitus, Type 1: 119 US clinical trials tracked, 39 recruiting.
Diabetes Mellitus, Type 1 is the subject of 119 registered US clinical trials on ClinicalTrials.gov, 39 of them currently open to new participants. 31 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 11 of these trials.
Enrollment posture brief
Registry condition diabetes-mellitus-type-1
OPEN 39 | RECR 33% | LATE 31 | EARLY 27 | RANK #105 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Non-alcoholic Fatty Liver Disease (33% recruiting · 58 trials)
Diabetes Mellitus, Type 1 lists 39 open slots (33% of 119 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetes Mellitus, Type 1 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetes Mellitus, Type 1 is recruiting below its size-band peers.
39 of 119 indexed trials (32.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diabetes Mellitus, Type 1 trials is spread across many organizations.
Novo Nordisk A/S accounts for 11 of 119 trials (9.2%). 70 distinct sponsors appear on at least one study for this condition label.
-
Typical Diabetes Mellitus, Type 1 enrolment sits around 73 participants.
Median target enrolment is 73 among the 119 trials that report a genuine target (sentinel values excluded). 70 of those (58.8%) plan for fewer than 100 participants.
-
Diabetes Mellitus, Type 1 research is mostly interventional.
105 interventional and 14 observational studies make up this index (88.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
119 total, page 2 of 3
Family-Based Treatment for Type 1 Diabetes
State University of New York at Buffalo
NCT05756361
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
Sanofi
NCT05757713
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
Novo Nordisk A/S
NCT01836523
The Loop Observational Study
Jaeb Center for Health Research
NCT03838900
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes
Novo Nordisk A/S
NCT02500706
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
Boehringer Ingelheim
NCT02414958
Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
Novo Nordisk A/S
NCT00982228
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
Novo Nordisk A/S
NCT04848480
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
Novo Nordisk A/S
NCT00978627
A Study in Adults With Type 1 Diabetes
Eli Lilly and Company
NCT01421147
NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
Novo Nordisk A/S
NCT00095446
Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes
Eli Lilly and Company
NCT00356109
Mylan Insulin Aspart Study
Mylan
NCT03760068
Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes
Eli Lilly and Company
NCT00127634
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
Novo Nordisk A/S
NCT01835431
Patient and Parent Preferences for an On-Body Automated Insulin Delivery System
Joslin Diabetes Center
NCT03534544
Afrezza® INHALE-1 Study in Pediatrics
Mannkind Corporation
NCT04974528
Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control
AstraZeneca
NCT00042458
Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus
Sanofi
NCT00607087
Post Approval Study of the Eversense® Continuous Glucose Monitoring
Senseonics
NCT03908125
Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose
Becton, Dickinson and Company
NCT00741390
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
Novo Nordisk A/S
NCT00773279
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
Duke University
NCT03938324
Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign
Scripps Whittier Diabetes Institute
NCT03068273
Day and Night Closed-loop in Young People With Type 1 Diabetes
Jaeb Center for Health Research
NCT02925299
Pilot Study of Brief Intervention to Support Diabetes Health-Related Quality of Life
Baylor College of Medicine
NCT05234944
Evaluation of TTP399 in Patients With Type 1 Diabetes
vTv Therapeutics
NCT03335371
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
Sangamo Therapeutics
NCT00406458
Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial
Tandem Diabetes Care
NCT03195140
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
Sangamo Therapeutics
NCT00476931
Clinical Startup of the 670G Closed Loop Insulin Delivery System
Stanford University
NCT03017482
Assessment of Mealtime Bolus Insulin Behavior
Eli Lilly and Company
NCT03368807
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Eli Lilly and Company
NCT01994746
Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00813228
Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index
University of Virginia
NCT02663661
Diabetes Visual Function Supplement Study
ZeaVision
NCT01646047
ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)
University of North Carolina, Chapel Hill
NCT03651622
Comparison of Glycemic Control Achieved With 2 Different Needles
Novo Nordisk A/S
NCT00572052
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
University of Colorado, Denver
NCT03618420
Green Digital Diabetes Waste Project
Florida State University
NCT06071325
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
Halozyme Therapeutics
NCT00883558
A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas
Massachusetts General Hospital
NCT02092220
Recurrent Hypoglycemia in Type 1 Diabetes (Aim 1)
University of Minnesota
NCT03410277
Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control
Diasome Pharmaceuticals
NCT03096392
Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus
University of Virginia
NCT00943787
Pilot Study of Connected Diabetes Technology
University of California, Davis
NCT04106440
A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
Novo Nordisk A/S
NCT01999322
A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes
Pfizer
NCT02038764
Medtronic Minimed Overnight Closed-Loop System
Bruce A. Buckingham
NCT01881009
Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study
University of Virginia
NCT01973413
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 14 |
| Phase 3 | 23 |
| Phase 4 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetes Mellitus, Type 1 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetes Mellitus, Type 1 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetes Mellitus, Type 1 page
119 registered trials, 39 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 39 Diabetes Mellitus, Type 1 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novo Nordisk A/S sponsors the most Diabetes Mellitus, Type 1 trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes Mellitus, Type 1 condition card totals 119 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.